|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (right-to-buy) | $ 28.6 | 08/31/2015 | M | 40,000 | (4) | 02/16/2017 | Common Stock | 40,000 | (7) | 0 | D | ||||
Stock Option (right-to-buy) | $ 19.36 | 08/31/2015 | M | 24,495 | (5) | 02/15/2018 | Common Stock | 24,495 | (7) | 0 | D | ||||
Stock Option (right-to-buy) | $ 17.45 | 08/31/2015 | M | 50,000 | (6) | 02/18/2021 | Common Stock | 50,000 | (7) | 15,000 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
SBLENDORIO GLENN 8 SYLVAN WAY PARSIPPANY, NJ 07054 |
X | President & CFO |
/s/ Stephen M. Rodin, Attorney-in-Fact for Glenn P. Sblendorio | 09/02/2015 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning March 1, 2015 and ending August 31, 2015. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on March 2, 2015. |
(2) | Sales were effected pursuant to a Rule 10b5-1 program adopted by the reporting person. |
(3) | Represents the weighted average sales price of the shares sold ranging from a low of $39.03 to a high of $40.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
(4) | This option vested in forty-eight equal installments beginning on March 16, 2007. |
(5) | This option vested in forty-eight equal installments beginning on March 15, 2008. |
(6) | This option vested in forty-eight equal installments beginning on March 18, 2011. |
(7) | Not applicable. |